Eli Lilly is a global pharmaceutical leader whose growth is dominated by its incretin (GLP-1) franchise — tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity — the fastest-growing drug class in history. Its core business is discovering, manufacturing and selling branded medicines, with a deep pipeline spanning obesity, diabetes, oncology, immunology and neuroscience (including an oral GLP-1 and next-generation obesity drugs). What sets it apart is a commanding, high-margin position in the enormous obesity/diabetes market, ~84% gross margins, and a best-in-class R&D engine. The risk is a very rich valuation and intensifying competition (Novo Nordisk, oral entrants). Think of it as the premier GLP-1 growth story — a superb business whose main question is whether the price already discounts the growth.
Lifecycle & sector: Large-cap pharma in accelerated growth (Health Care). Scored on the GLP-1 franchise, margins, R&D productivity and patent/pipeline durability.
| Sub-signal | Reading | Score |
|---|---|---|
| Growth | Revenue +~30%+ on tirzepatide (Mounjaro/Zepbound) — fastest-growing drug class | 88 |
| Margins | Gross ~84%, operating ~46% — elite pharma economics | 88 |
| Pipeline / R&D | Oral GLP-1 + next-gen obesity, oncology, neuro — deep and productive | 82 |
| Patent durability | GLP-1 IP runway solid near-term; watch late-decade cliffs | 70 |
| Rival | Type | Lilly's position |
|---|---|---|
| Novo Nordisk | Direct GLP-1 rival | Gaining — tirzepatide efficacy edge, but Novo is formidable and price-competing |
| Oral GLP-1 / next-gen (Viking, Amgen, Pfizer) | Disruptive entrants | At risk — orals/new mechanisms could erode share and pricing |
| Payers / policy | Pricing pressure | Watch — formulary and government pricing on GLP-1s |
Warranted-multiple anchor. r ≈ 9.0%; disciplined g_near ≈ 10-12% (pharma cap, haircut — even proven GLP-1 growth is capped), g_term 3% → warranted P/E ≈ 23x. Clean forward P/E ≈ 30x → ~1.3x (Full); TTM P/E ≈ 42x → ~1.85x (Expensive). Net: Expensive.
| Lens | Reading | Score |
|---|---|---|
| Warranted-multiple anchor (40%) | Fwd 30x / TTM 42x ÷ warranted 23x → Full-to-Expensive | 34 |
| FCF yield | Low — heavy capacity capex; P/FCF ~83x | 30 |
| PEG | Low PEG on explosive growth — but the anchor haircuts growth by design (anti-hype) | 48 |
| Analyst target | Consensus US$1,278 / median US$1,281 vs US$1,200 — only ~6% upside | 50 |
Primary driver: the enormous, fast-growing obesity/diabetes GLP-1 market — a genuine structural tailwind, moderated by intensifying competition.
| Horizon | Read | Driver |
|---|---|---|
| Short | GLP-1 demand outstripping supply; strong scripts | ~78 Tailwind |
| Medium | Capacity ramp + Zepbound growth; competition rising | ~78 Tailwind |
| Long | Huge TAM, but orals/next-gen + pricing pressure temper it | ~72 Tailwind |
Amplification: the driver is a strong tailwind, but the base signal is HOLD (never amplified) and the Expensive valuation caps it. Thesis-invalidation floor: a competitive readout (Novo/oral) taking share or a formulary/pricing shock puncturing the growth-and-multiple.
Health Care (XLV) is Neutral; LLY's returns are franchise/idiosyncratic (GLP-1), not macro-driven. Neutral pressure enables no amplification and leaves the HOLD unchanged.
Source: sector-map (Health Care/XLV) · Macro report 2026-07-03
Risk-reward: LLY is at ~US$1,200, a fresh all-time high, in a strong uptrend on every timeframe with RSI ~67 (near overbought). Momentum is excellent; the problem is you're paying an Expensive multiple with no cushion and only ~6% upside to consensus.
| Signal | Reading | Score |
|---|---|---|
| Trend structure | Strong uptrend all TFs; above all MAs; at ATH | 72 |
| Momentum | RSI ~67 — strong but extended/overbought | 56 |
| Position in range | At the 52-wk high — extended | 50 |
| Valuation support | None — Expensive band, ~6% to consensus | 38 |
| Timeframe | Trend | Direction | RSI | MACD | Key S/R | Breakout | Vol |
|---|---|---|---|---|---|---|---|
| Monthly | Uptrend | Bullish | 68 | + | S: 623 R: 1134 | Breakout | 0.1x |
| Weekly | Uptrend | Bullish | 67 | + | S: 850 R: 1134 | Breakout | 0.2x |
| Daily | Strong Up | Bullish | 67 | + | S: 943 R: 1238 | Breakout | 0.9x |
| Confluence: Strongly bullish (trend) / expensive (value) · MTF Score 58 | |||||||
A powerful uptrend at new highs — the trend is not the issue, the valuation is. A push through US$1,238 extends the run; a loss of US$1,133 would be the first crack, and with no valuation cushion and an elevated competitive threat, a de-rate could be sharp. RSI ~67 flags it's extended.
LLY weekly close (Yahoo), Jan–Jul 2026. Strong uptrend to new highs (~US$1,200); Expensive valuation.
GLP-1 demand keeps outrunning supply, pipeline readouts land, and the multiple holds; new highs toward the Street high. ~+17%.
Strong growth but a rich multiple and rising competition cap the re-rate; grinds with earnings. ~+7%.
A competitive readout (Novo / oral GLP-1) takes share, or a pricing/formulary shock, and the Expensive multiple de-rates toward ~23x. ~−21%. Trigger: a share-loss print or a pricing shock (the elevated competitive threat).
Probability-weighted 12-month fair value ≈ US$1,228 (~+2%) — essentially flat: a superb franchise, but an Expensive multiple and an elevated competitive threat cap the reward and fatten the left tail.
Forecast: No group met → Wait. Fundamental can't fire in the Expensive band; Technical is overbought at the high (RSI 67). The entry edge opens on a pullback toward US$1,133 (or a de-rate), or a step-up that grows into the multiple — chasing a ~30x-forward name at an all-time high into an elevated competitive threat is the setup the framework counsels against.
Forecast: Stop (US$1,133) ~6% below; a break there in a competitive/pricing scare is the tail the Bear models. No exit trigger live today.
What you're risking: paying ~30x forward (42x trailing) for a superb franchise at an all-time high, overbought, with only ~6% upside to consensus and an elevated competitive threat (Novo, orals). What you're gaining: the premier GLP-1 growth story with elite margins and a deep pipeline. Read: the business is not the question — the price is. Wait for a pullback to US$1,133 or a de-rate; this is a HOLD, not an entry.
What you'd protect: the left tail if a competitor readout or pricing shock de-rates the Expensive multiple. What you'd give up: continued GLP-1 growth. No profit-target is mechanically live. Read: a hold for long-term owners; new money has no edge at ~30x forward at an ATH.
Position sizing not computed — no risk budget on file. The §12 Conviction Ladder reads Wait (0 of 3 met): a superb franchise with no entry edge at ~30x forward at an all-time high. This is context, not advice.
{
"ticker": "LLY",
"date": "2026-07-06",
"version": "v6",
"company": "Eli Lilly and Company",
"currency": "USD",
"exchange": "NYSE",
"exchange_ticker": "NYSE:LLY",
"isin": "US5324571083",
"api_ticker": "LLY",
"analysis_status": "on-going",
"lifecycle_stage": "large_cap_pharma_accelerated_growth",
"sector": "Health Care",
"gics_sector": "Health Care",
"country": "United States",
"finder_ticker": "LLY",
"price_at_rating": 1200.06,
"signal_short": "HOLD",
"signal_medium": "HOLD",
"signal_long": "HOLD",
"primary_signal": "HOLD",
"quality_score": 84,
"valuation_score": 35,
"timing_score": 58,
"driver_score": 78,
"economic_alignment_stance": "Neutral",
"economic_alignment_conviction": 54,
"economic_alignment_pressure": "Neutral",
"economic_alignment_source": "sector-map",
"macro_report_date": "2026-07-03",
"overall_confidence": 56,
"val_band": "expensive",
"warranted_multiple": 23,
"actual_multiple": 30,
"warranted_ratio": 1.3,
"clean_pe": 30.0,
"nonop_pct_of_net_income": -8,
"val_multiple_basis": "clean forward P/E (TTM ~42x)",
"fair_value_est": 1200,
"stop_loss": 1133,
"target_price": 1280,
"scenario_base_target": 1280,
"scenario_bull_target": 1400,
"scenario_bear_target": 950,
"entry_groups_met": 0,
"entry_conviction": "Wait",
"exit_groups_live": 0,
"exit_action": "Hold",
"hard_gate_state": "caution",
"gates_triggered": [],
"gates_caution": [
"Valuation Ceiling",
"Competitive/Business Model"
],
"do_not_buy_triggers": [],
"competitive_share_trajectory": "gaining",
"competitive_threat_level": "elevated",
"analyst_consensus_target": 1278.18,
"analyst_target_high": 1400,
"analyst_target_low": 1135,
"analyst_coverage_count": 45,
"next_update_date": "2026-07-20",
"next_update_basis": "default +14d (Q2 earnings early Aug beyond window)",
"prior_report": "calibration-LLY-20260622-1305.json",
"prior_primary": "HOLD",
"changes_note": "HOLD held; richened by +9% to a fresh ATH. Fwd ~30x / TTM ~42x vs warranted ~23x = Expensive; competitive threat elevated (Novo/orals) in Bear. ~6% to consensus, overbought. Entry Wait."
}
HOLD held across all horizons; richened by the +9% run to a fresh all-time high. Clean forward P/E ~30x (TTM ~42x) vs a warranted ~23x sits in the Expensive band, and the competitive threat is ELEVATED (Novo, oral GLP-1 entrants, pricing pressure) — carried into the Bear. Only ~6% upside to consensus and overbought (RSI ~67). A superb GLP-1 franchise at a rich price; entry ladder Wait. Health Care is funded in the portfolio but a HOLD earns no grid tile.